Company: PSTV
Filing Date: 2025-04-30
Form Type: 10-K/A
Source: 0000950170-25-061028
Chunk: 2

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-30
Form: 10-K/A
Chunk 2
---
, 2025, there were 16,999,626 shares of the registrant’s common stock issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE None.

EXPLANATORY NOTE This Amendment No. 1 to Form 10-K (this “Amendment”) amends the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 originally filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025 (the “Original Filing”) by Plus Therapeutics, Inc., a Delaware corporation (“Plus,” the “Company,” “we,” or “us”). We are filing this Amendment pursuant to General Instruction G(3) of Form 10-K to include information required by Part III, Items 10 through 14 of the 2024 Form 10-K. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by the Company’s principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002 (the “302 Certifications”) are being filed as exhibits to this Amendment. Because no financial statements are contained within this Amendment, we are not filing currently dated certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Accordingly, in addition to amending Items 10 through 14 of Part III to provide the omitted information, Item 15 of Part IV and the List of Exhibits referenced therein are being amended and restated in their entirety to include the new 302 Certifications. This Amendment also amends the cover page to update the number of shares of the Company’s common stock, par value $0.001 per share (the “common stock”), outstanding and to remove the statement that information is being incorporated by reference from our definitive proxy statement. Except as described above, no other changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing, and we have not updated the disclosures contained therein to reflect any events which occurred at a date subsequent to the filing of the Original Filing. TABLE OF CONTENTS

|          | PART III                                                                                       |    |
| Item 10. | Directors, Executive Officers and Corporate Governance                                         |  3 |
| Item 11. | Executive Compensation                                                                         |  7 |
| Item 12. | Security Ownership of Certain Beneficial Owners and